FV-100 News
Most Popular FV-100 Story
Inhibitex shares crater as lead drug flunks Ph2
Shares of Inhibitex ($INHX) slid 25 percent on the news that its lead drug for shingles failed a mid-stage trial. Investigators recruited 350 patients to test two doses of FV-100 against GSK's Read more...
Latest Headlines
- December 14, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
